US 12116622
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
granted A61KA61K2039/505A61K39/001135
Quick answer
US patent 12116622 (Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF) held by REGENERON PHARMACEUTICALS, INC. expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 28
- CPC classes
- A61K, A61K2039/505, A61K39/001135, A61P, A61P27/00